NCT06009393View on ClinicalTrials.gov

Evaluate the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 22, 2023

Primary Completion Date

June 29, 2024

Study Completion Date

August 23, 2024

Conditions

Homozygous Familial Hypercholesterolemia

Interventions

DRUG

SHR-1918

Three administration

Trial Locations (1)

410007

The Second Xiangya Hospital of Central South University Hospital, Changsha

All Listed Sponsors

lead

Beijing Suncadia Pharmaceuticals Co., Ltd

INDUSTRY

NCT06009393 - Evaluate the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia | Biotech Hunter | Biotech Hunter